Greenwich LifeSciences, Inc.

Contributing Author

Recent Articles by Greenwich LifeSciences, Inc.

5 hours	Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 GLSI +5.72% GlobeNewswire
Jun-01	Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026 GLSI +8.92% GlobeNewswire
Jun-01	Greenwich LifeSciences Provides Update Regarding Form 10-K Filing GLSI +8.92% GlobeNewswire
May-22	Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing GLSI GlobeNewswire
Apr-30	Greenwich LifeSciences Provides Update Regarding Form 10-K Filing GLSI +9.35% GlobeNewswire
Apr-23	Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026 GLSI -5.09% GlobeNewswire
Apr-22	Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing GLSI +8.86% GlobeNewswire
Apr-20	Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026 GLSI -11.61% GlobeNewswire
Apr-14	Greenwich LifeSciences Provides Update on Financing Strategy GLSI -5.35% GlobeNewswire
Apr-07	Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential GLSI GlobeNewswire
Mar-19	Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01 GLSI GlobeNewswire
Mar-18	Greenwich LifeSciences Provides Update on Upcoming AACR Meeting GLSI -11.11% GlobeNewswire
Mar-17	Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01 GLSI +6.83% GlobeNewswire
Mar-16	Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 GLSI +5.20% GlobeNewswire
Mar-03	Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 GLSI GlobeNewswire
Feb-24	Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 GLSI +9.60% GlobeNewswire
Jan-27	Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy GLSI +9.62% GlobeNewswire
Jan-22	Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01 GLSI +5.65% GlobeNewswire
Dec-29	Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 GLSI +19.80% GlobeNewswire
Dec-22	Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy GLSI GlobeNewswire
Dec-15	Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 GLSI GlobeNewswire
Dec-08	Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 GLSI +7.49% GlobeNewswire
Dec-03	Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date GLSI +5.12% GlobeNewswire
Oct-09	Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial GLSI GlobeNewswire
Oct-02	Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium GLSI +5.34% GlobeNewswire
Sep-30	Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial GLSI GlobeNewswire
Sep-18	Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland GLSI GlobeNewswire
Sep-10	Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation GLSI GlobeNewswire
Aug-20	Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences GLSI GlobeNewswire
Aug-19	Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team GLSI GlobeNewswire
Aug-13	Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania GLSI GlobeNewswire
Aug-11	Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events GLSI GlobeNewswire

Greenwich LifeSciences, Inc.

Recent Articles by Greenwich LifeSciences, Inc.

Upgrade your Finviz experience